Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

A roundup of what The Globe and Mail's market strategist Scott Barlow is reading today on the Web

In a helpful podcast, ETF expert Todd Rosenbluth explains how to tell if your ETF, or a prospective ETF investment, measures up,

"Start by evaluating the holdings, weightings, and costs, and then you can start wading into next-level stuff like liquidity and volatility. By the end of this episode, you'll learn how expert analysts view any ETF."

Story continues below advertisement

"Here's an Easy Checklist to Evaluate Any ETF" – Trillions (Bloomberg podcast)

====

For investors with access to Financial Times, the orange newspaper people published an excellent Year in Charts review of 2017. The charts include President Trump's approval rating, 'Bitcoin is in classic bubble territory,' and the graphic below showing that while growth in renewable power generation is strong, it is still dwarfed by fossil fuel usage,

" @SBarlow_ROB From the FT's excellent Year in Charts amp.ft.com/content/7020a6… " – Financial Times, Twitter (includes link to full story)

=====

Crude prices have been strong in recent days and this Reuters report cites experts predicting this is the beginning of a trend,

"'Oil demand will be high in 2018, with solid economic growth worldwide ... Supply will be relatively tight because of high OPEC commitment,' said Frank Schallenberger, head of commodity research at LBBW."

Story continues below advertisement

"Poll: Supply discipline and demand to prop up oil prices in 2018" – Reuters

"Five Oil Signals to Watch in 2018" – Bloomberg

"Oil Trades Near Two-Year High After Libya Pipeline Explosion" – Bloomberg

=====

Gene editing technology is ethically terrifying to me in the long term, but it has incredible power to prevent the onset of horrifying diseases. The M.I.T. Technology Review believes this is the year when the technology will be applied to human health on a wide scale,

"Gene editing hasn't cured disease in a human being yet—but it is getting closer. With the debut of CRISPR a few years ago, advances in the technology have been happening at a breakneck pace… [In 2017], The first human embryos in the U.S. were modified with CRISPR. In August, researchers at Oregon Health and Science University, led by Shoukhrat Mitalipov, reported the first known attempt at genetically modifying human embryos in the U.S. They injected CRISPR into embryos that carried a genetic mutation responsible for an often fatal hereditary heart condition. CRISPR was able to correct the mutation in about three-quarters of the embryos."

Story continues below advertisement

"Four Amazing Things Gene Editing Did in 2017" – MIT Technology Review

"In 2018, We Will CRISPR Human Beings" – Gizmodo

=====

The U.S. holiday shopping season suggests the dreaded Retail Apocalypse might be delayed,

"The holiday shopping season, a crucial period for retailers that can account for up to 40 percent of annual sales, brought record-breaking online and in-store spending this year of more than $800 billion, according to Mastercard Inc's analytics arm … 'It has been an extremely positive holiday season in terms of sales both for brick-and-mortar and for online businesses,' said Shelley Kohan, a Retail Fellow at analytics firm RetailNext."

"U.S. holiday sales set to break records in surprise boon to retail" – Reuters

Story continues below advertisement

"@JeffMacke Spoiler: about 1/2 of these rallies in retail are going to give it all back and then some. The magic is determining which half..." – Twitter

=====

Tweet of the Day: "@tbiesheuvel Pow. Copper jumps to the highest in three years bloomberg.com/news/articles/… " – Twitter

Diversion: "How Fleetwood Mac Makes A Song" – Youtube

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Comments are closed

We have closed comments on this story for legal reasons or for abuse. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies